The FDA has greenlit a new oral obesity drug that rivals injectable GLP-1s but with milder GI side effects in trial data.
Pharma analysts expect rapid adoption given the pill's convenience and projected pricing.
Insurers are already reviewing coverage policies for the breakthrough therapy.
